Biosimilar switching – current state of knowledge

Evidence from over 10 years of clinical experience demonstrates that biosimilar medicines approved in the European Union can be used for all their registered indications as safely as their originators and with no negative impact on therapeutic efficacy. The debate on the use of biosimilars in rheuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiland, Piotr, Batko, Bogdan, Brzosko, Marek, Kucharz, Eugeniusz J., Samborski, Włodzimierz, Świerkot, Jerzy, Więsik-Szewczyk, Ewa, Feldman, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142020/
https://www.ncbi.nlm.nih.gov/pubmed/30237628
http://dx.doi.org/10.5114/reum.2018.77975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142020/
https://www.ncbi.nlm.nih.gov/pubmed/30237628
http://dx.doi.org/10.5114/reum.2018.77975

Ejemplares similares